While long considered to be undruggable, recently the approval of sotorasib revolutionized the targeting of KRAS mutant NSCLC, with adagrasib as another G12C targeting TKI expected to receive FDA approval following promising results from the phase II Krystal-1 trial as well [67]. Here, KRAS is linked to non-small cell lung carcinoma.